FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296810026> ?p ?o ?g. }

• W4296810026 endingPage "135" @default.
• W4296810026 startingPage "125" @default.
• W4296810026 abstract "Beta thalassemia is associated with decreased immunity possibly due to iron overload. Al-hijamah (Hijamah) is wet cupping therapy (WCT) of prophetic medicine. Prophet Muhammad Peace be upon him said: The best among your treatments is Al-hijamah. Al-hijamah is a promising excretory treatment to clear blood of causative pathological substances. Al-hijamah is a three-step technique (skin suction, scarification and suction) i.e. triple S technique). Recently, we introduced Al-hijamah as a novel iron excretion therapy (through pressure-dependent filtration then excretion via the skin dermal capillaries) that significantly decreased serum iron overload and related oxidative stress using a physiological excretory mechanism (Taibah mechanism). Iron overload was reported to impair both humoral immunity and cell mediated immunity in patients with beta thalassemia. In this study, twenty patients having β-thalassemia major (maintained on iron chelation therapy) underwent a single session of Al-hijamah (30-60 minutes) using 4-5 sucking cups only. Another age and sex-matched control group of thalassemic patients received iron chelation therapy only. Al-hijamah enhanced the immunity of thalassemic patients in the form of increased CD4+ T cell count, from 124.10±36.98 to 326.20±57.94 cells/mm3, and an increased CD8+ T cell count from 100.30±36.98 to 272.40±46.37 cells/mm3. CD4/CD8 ratio significantly increased from 1.29 to 1.7 (P<0.001). There was a significant increase of ten times (P<0.001) in serum TAC/MDA ratio (reflects increased antioxidant capacity vs decreased oxidative load and stress) induced by Al-hijamah. After Al-hijamah, both CD4+ and CD8+ T cell counts significantly increased and positively correlated with TAC/MDA ratio (r = 0.246) and (r = 0.190), respectively. Moreover, CD4/CD8 ratio positively correlated with TAC/MDA after Al-hijamah (r = 0.285). In conclusion, Al-hijamah significantly increased CD4/CD8 ratio in thalassemic patients via increasing TAC/MDA ratio. Our study strongly recommends medical practice of Al-hijamah in hospitals for its immune potentiating effects in agreement with the evidence-based Taibah mechanism. Al-hijamah should be generalized for treating other immune-deficiency conditions. Al-hijamah-induced bloody excretion is so minimal and never aggravates the anaemic status." @default.
• W4296810026 created "2022-09-24" @default.
• W4296810026 creator A5003440178 @default.
• W4296810026 creator A5009175224 @default.
• W4296810026 creator A5012363138 @default.
• W4296810026 creator A5023595885 @default.
• W4296810026 creator A5025532083 @default.
• W4296810026 creator A5028080275 @default.
• W4296810026 creator A5029341360 @default.
• W4296810026 creator A5030109402 @default.
• W4296810026 creator A5034420769 @default.
• W4296810026 creator A5038606821 @default.
• W4296810026 creator A5052694356 @default.
• W4296810026 creator A5055286396 @default.
• W4296810026 creator A5056498247 @default.
• W4296810026 creator A5059471369 @default.
• W4296810026 creator A5060834472 @default.
• W4296810026 creator A5064025539 @default.
• W4296810026 creator A5068336096 @default.
• W4296810026 creator A5069580812 @default.
• W4296810026 creator A5073931573 @default.
• W4296810026 creator A5081029029 @default.
• W4296810026 creator A5087366365 @default.
• W4296810026 creator A5087576373 @default.
• W4296810026 creator A5088940701 @default.
• W4296810026 date "2022-01-01" @default.
• W4296810026 modified "2023-10-01" @default.
• W4296810026 title "Al-hijamah (the triple S treatment of prophetic medicine) significantly increases CD4/CD8 ratio in thalassemic patients via increasing TAC/MDA ratio: a clinical trial." @default.
• W4296810026 cites W176746596 @default.
• W4296810026 cites W1785988192 @default.
• W4296810026 cites W1983784119 @default.
• W4296810026 cites W2164069806 @default.
• W4296810026 cites W2466878957 @default.
• W4296810026 cites W2558354861 @default.
• W4296810026 cites W2902207938 @default.
• W4296810026 cites W2904870985 @default.
• W4296810026 cites W2981780879 @default.
• W4296810026 cites W3123279038 @default.
• W4296810026 cites W3197972938 @default.
• W4296810026 cites W4205358133 @default.
• W4296810026 cites W4205700212 @default.
• W4296810026 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36147606" @default.
• W4296810026 hasPublicationYear "2022" @default.
• W4296810026 type Work @default.
• W4296810026 citedByCount "2" @default.
• W4296810026 countsByYear W42968100262023 @default.
• W4296810026 crossrefType "journal-article" @default.
• W4296810026 hasAuthorship W4296810026A5003440178 @default.
• W4296810026 hasAuthorship W4296810026A5009175224 @default.
• W4296810026 hasAuthorship W4296810026A5012363138 @default.
• W4296810026 hasAuthorship W4296810026A5023595885 @default.
• W4296810026 hasAuthorship W4296810026A5025532083 @default.
• W4296810026 hasAuthorship W4296810026A5028080275 @default.
• W4296810026 hasAuthorship W4296810026A5029341360 @default.
• W4296810026 hasAuthorship W4296810026A5030109402 @default.
• W4296810026 hasAuthorship W4296810026A5034420769 @default.
• W4296810026 hasAuthorship W4296810026A5038606821 @default.
• W4296810026 hasAuthorship W4296810026A5052694356 @default.
• W4296810026 hasAuthorship W4296810026A5055286396 @default.
• W4296810026 hasAuthorship W4296810026A5056498247 @default.
• W4296810026 hasAuthorship W4296810026A5059471369 @default.
• W4296810026 hasAuthorship W4296810026A5060834472 @default.
• W4296810026 hasAuthorship W4296810026A5064025539 @default.
• W4296810026 hasAuthorship W4296810026A5068336096 @default.
• W4296810026 hasAuthorship W4296810026A5069580812 @default.
• W4296810026 hasAuthorship W4296810026A5073931573 @default.
• W4296810026 hasAuthorship W4296810026A5081029029 @default.
• W4296810026 hasAuthorship W4296810026A5087366365 @default.
• W4296810026 hasAuthorship W4296810026A5087576373 @default.
• W4296810026 hasAuthorship W4296810026A5088940701 @default.
• W4296810026 hasConcept C10146269 @default.
• W4296810026 hasConcept C126322002 @default.
• W4296810026 hasConcept C134018914 @default.
• W4296810026 hasConcept C167672396 @default.
• W4296810026 hasConcept C185592680 @default.
• W4296810026 hasConcept C203014093 @default.
• W4296810026 hasConcept C2776151105 @default.
• W4296810026 hasConcept C2776517179 @default.
• W4296810026 hasConcept C2777799968 @default.
• W4296810026 hasConcept C2778004101 @default.
• W4296810026 hasConcept C2779341262 @default.
• W4296810026 hasConcept C55493867 @default.
• W4296810026 hasConcept C71924100 @default.
• W4296810026 hasConcept C8891405 @default.
• W4296810026 hasConcept C90924648 @default.
• W4296810026 hasConceptScore W4296810026C10146269 @default.
• W4296810026 hasConceptScore W4296810026C126322002 @default.
• W4296810026 hasConceptScore W4296810026C134018914 @default.
• W4296810026 hasConceptScore W4296810026C167672396 @default.
• W4296810026 hasConceptScore W4296810026C185592680 @default.
• W4296810026 hasConceptScore W4296810026C203014093 @default.
• W4296810026 hasConceptScore W4296810026C2776151105 @default.
• W4296810026 hasConceptScore W4296810026C2776517179 @default.
• W4296810026 hasConceptScore W4296810026C2777799968 @default.
• W4296810026 hasConceptScore W4296810026C2778004101 @default.
• W4296810026 hasConceptScore W4296810026C2779341262 @default.
• W4296810026 hasConceptScore W4296810026C55493867 @default.
• W4296810026 hasConceptScore W4296810026C71924100 @default.

• next